Caveolin-1 regulates chemokine receptor 5-mediated contribution of bone marrow-derived cells to dermal fibrosis

Rebecca Lee, Beth Perry, Jonathan Heywood, Charles Reese, Michael Bonner, Corey M. Hatfield, Richard M. Silver, Richard P. Visconti, Stanley Hoffman, Elena TourkinaFrontiers in Pharmacology 2014 · DOI

TL;DR

This study reveals that the protein caveolin-1 plays a crucial role in regulating dermal fibrosis, particularly in the context of scleroderma (SSc). By targeting the chemokine receptor CCR5 and its ligands, a peptide called CSD effectively blocks the recruitment of bone marrow-derived cells, thereby reducing fibrosis and restoring adipose tissue. This suggests CSD as a promising therapeutic agent for fibrotic diseases.

What Problem Does This Paper Address?

Fibrotic diseases, such as scleroderma (SSc), are characterized by excessive collagen deposition and tissue remodeling, leading to organ dysfunction and potentially death. While resident fibroblasts were traditionally thought to be the primary drivers of fibrosis, recent research highlights the significant contribution of bone marrow-derived cells, particularly monocytes that differentiate into fibrocytes. These fibrocytes, in turn, can further differentiate into fibroblasts. A key question in understanding and treating these diseases is how these cells are recruited to the fibrotic tissue and what molecular mechanisms regulate this process. Specifically, the role of caveolin-1, a protein known to be underexpressed in fibrotic conditions, and its impact on monocyte/fibrocyte migration via chemokine receptors like CCR5, remained to be fully elucidated in the context of dermal fibrosis.

Methods

The researchers employed a multi-pronged approach:

  • Murine Model of Dermal Fibrosis: They utilized a "Pump Model" where bleomycin was delivered systemically via osmotic minipumps to induce fibrosis in mice, mimicking key aspects of human SSc, including lung, skin, and internal organ fibrosis.
  • Caveolin-1 Scaffolding Domain Peptide (CSD) Treatment: The CSD peptide, which mimics the function of full-length caveolin-1, was administered to mice to assess its therapeutic potential in blocking bleomycin-induced fibrosis and restoring adipose tissue.
  • Histopathological Analysis: Skin sections from both mice and human SSc patients were analyzed using Hematoxylin and Eosin (H&E) and Masson's Trichrome (MT) staining to assess dermal thickness and collagen deposition.
  • Immunohistochemistry and Immunofluorescence: This was crucial for identifying and quantifying specific cell populations and protein markers. They used antibodies against CD45 (a leukocyte marker), Procollagen I (a marker for fibrocytes and fibroblasts), CCR5 (a chemokine receptor), and its ligands (MIP1α and MIP1β).
  • Monocyte and Bone Marrow Cell Migration Assays: In vitro assays were performed to measure the migratory capacity of monocytes isolated from SSc patients and bone marrow cells from mice towards CCR5 ligands, both in the presence and absence of CSD.
  • Western Blotting: Used to assess the expression levels of CCR5 in SSc monocytes.

Datasets

The study utilized:

  • Murine Skin Samples: From CD1 mice treated with bleomycin and/or CSD.
  • Human Skin Biopsies: From eight human subjects (four SSc patients and four healthy controls).
  • Human Peripheral Blood Mononuclear Cells (PBMCs): Isolated from SSc patients and healthy controls for monocyte isolation.

No new benchmarks were introduced; the study focused on validating existing models and techniques.

Key Insights and Ideas

  • Caveolin-1 Deficiency Drives Fibrosis: The study strongly suggests that low caveolin-1 levels in monocytes are a key driver of dermal fibrosis by promoting their migration and differentiation into fibrotic cells.
  • CSD as a "Caveolin-1 Mimic": The CSD peptide effectively compensates for caveolin-1 deficiency, reversing the profibrotic effects. This highlights the therapeutic potential of targeting the caveolin-1 scaffolding domain.
  • CCR5 as a Central Mediator: The chemokine receptor CCR5 and its ligands (MIP1α and MIP1β) are identified as critical players in the recruitment of bone marrow-derived cells to fibrotic skin.
  • Fibrocytes are Key Players in SSc Skin: The research confirms the significant accumulation of fibrocytes (CD45+/Procollagen I+) in the fibrotic dermis of both SSc patients and the bleomycin-induced mouse model.
  • Unexpected Adipose Tissue Restoration: Beyond blocking fibrosis, CSD also reversed the bleomycin-induced thinning of the subcutaneous adipose layer, even promoting adipose tissue thickness in control mice. This suggests a broader role for caveolin-1 in adipocyte function.

Key Results

  • Dermal Thickness: Bleomycin treatment increased dermal thickness by approximately 2-fold in the Pump Model mice, an effect almost completely blocked by CSD (p < 0.001).
  • Subcutaneous Fat Layer: The subcutaneous fat layer became over 80% thinner in bleomycin-treated mice, an effect also reversed by CSD.
  • Fibrocyte Accumulation: Fibrocytes were found at >5-fold higher levels in the fibrotic dermis of SSc patients and Pump Model mice compared to controls. CSD treatment significantly inhibited this accumulation.
  • CCR5 and Ligand Accumulation: Cells positive for CCR5 and its ligands (MIP1α, MIP1β) were also significantly increased in fibrotic skin and were reduced by CSD.
  • Monocyte Migration: Migration of SSc monocytes and Pump Model bone marrow cells towards CCR5 ligands was 3-fold greater than controls and was almost completely blocked by CSD.

Limitations and Future Work

  • Mechanism of Adipose Tissue Effects: While CSD restored adipose tissue, the precise mechanisms underlying this effect and its relationship to fibrosis require further investigation. The authors speculate on the role of caveolin-1 in regulating the differentiation of pluripotent cells into myofibroblasts or adipocytes.
  • Broader Therapeutic Potential: The study strongly suggests CSD as a potential treatment for fibrotic diseases of the skin and other organs, but further clinical trials would be necessary to validate this.
  • CCR5 and CXCR4 in SSc: The paper notes that both CCR5 and CXCR4 are overexpressed on SSc monocytes, leading to hypermigration. While CSD blocks CCR5-mediated migration, further research could explore its impact on CXCR4-mediated pathways in SSc.
  • Caveolin-1 and G-Protein Signaling: The authors briefly mention the known interaction between caveolin-1 and G proteins, suggesting a potential molecular link for CCR5 regulation, which warrants deeper exploration.

Summary updated

Abstract

In fibrotic diseases caveolin-1 underexpression in fibroblasts results in collagen overexpression and in monocytes leads to hypermigration. These profibrotic behaviors are blocked by the caveolin-1 scaffolding domain peptide (CSD) which compensates for caveolin-1 deficiency. Monocytes and fibroblasts are related in that monocytes are the progenitors of fibrocytes (CD45+/Collagen I+ cells) that, in turn, are the progenitors of many fibroblasts in fibrotic tissues. In an additional anti-fibrotic activity, CSD blocks monocyte differentiation into fibrocytes. We studied a mouse fibrosis model (Pump Model) involving systemic bleomycin delivery that closely models scleroderma (SSc) in several ways, the most important of which for this study is that fibrosis is observed in the lungs, skin, and internal organs. We show here that dermal thickness is increased 2-fold in the Pump Model and that this effect is almost completely blocked by CSD (p < 0.001). Concomitantly, the subcutaneous fat layer becomes >80% thinner. This effect is also blocked by CSD (p < 0.001). Even in mice receiving vehicle instead of bleomycin, CSD increases the thickness of the fat layer. To study the mechanisms of action of bleomycin and CSD, we examined the accumulation of the chemokine receptor CCR5 and its ligands MIP1α and MIP1β in fibrotic tissue and their roles in monocyte migration. Fibrocytes and other leukocytes expressing CCR5 and its ligands were present at high levels in the fibrotic dermis of SSc patients and Pump Model mice while CSD blocked their accumulation in mouse dermis. Migration toward CCR5 ligands of SSc monocytes and Pump Model bone marrow cells was 3-fold greater than cells from control subjects. This enhanced migration was almost completely blocked by CSD. These results suggest that low monocyte caveolin-1 promotes fibrosis by enhancing the recruitment of fibrocytes and their progenitors into affected tissue.
BibTeX
@inproceedings{lee2014caveolin,
  author = {Rebecca Lee and Beth Perry and Jonathan Heywood and Charles Reese and Michael Bonner and Corey M. Hatfield and Richard M. Silver and Richard P. Visconti and Stanley Hoffman and Elena Tourkina},
  title = {{Caveolin-1 regulates chemokine receptor 5-mediated contribution of bone marrow-derived cells to dermal fibrosis}},
  booktitle = {Frontiers in Pharmacology},
  year = {2014},
  doi = {10.3389/fphar.2014.00140},
}
Figure